Toll interacting protein (TOLLIP) serum concentration in patients with systemic sclerosis (SSc), with and without interstitial lung disease (ILD).

BMJ Open Respir Res · 2026 · PMC13264915 · PMID 42264885

Europe PMC DOI

hedged sentences

0.1920

closest p · 3.8× alpha

0.1920

boldest claim

The sentences

showed a trendp=0.192not close (p > 0.1)

Patients with low TOLLIP serum concentrations (<0.1135 ng/μL) showed a trend towards shorter progression-free survival with a higher rate of disease progression compared with the TOLLIP-high group (36% vs 19%, p=0.192, respectively) ( online supplemental figure S1 ).

also in 53,322 other papers

a clear trendno p-value reported

Third, despite a clear trend towards lower serum TOLLIP concentrations in patients with SSc compared with HCs, considerable overlap between groups was observed, limiting its utility as a standalone diagnostic biomarker.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.